In their study, the combination of HDAC inhibitor SAHA with anti-PD-1 in breast tumor-bearing mice suppressed tumor cell proliferation, promoted inflammatory responses, and increased the numbers of tumor-infiltrating T lymphocytes in vivo. This evidence concerns the gene HDAC9 and breast neoplasm.